KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $14.2 million.

  • Inovio Pharmaceuticals' Non-Current Assets fell 995.06% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.5 million, marking a year-over-year decrease of 1008.7%. This contributed to the annual value of $15.4 million for FY2024, which is 1385.31% down from last year.
  • Inovio Pharmaceuticals' Non-Current Assets amounted to $14.2 million in Q3 2025, which was down 995.06% from $15.5 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Non-Current Assets ranged from a high of $66.4 million in Q1 2021 and a low of $14.2 million during Q3 2025
  • Moreover, its 5-year median value for Non-Current Assets was $29.8 million (2023), whereas its average is $30.7 million.
  • In the last 5 years, Inovio Pharmaceuticals' Non-Current Assets skyrocketed by 481.47% in 2021 and then tumbled by 5610.63% in 2023.
  • Inovio Pharmaceuticals' Non-Current Assets (Quarter) stood at $47.5 million in 2021, then dropped by 29.91% to $33.3 million in 2022, then crashed by 46.42% to $17.8 million in 2023, then dropped by 13.85% to $15.4 million in 2024, then dropped by 7.56% to $14.2 million in 2025.
  • Its Non-Current Assets stands at $14.2 million for Q3 2025, versus $15.5 million for Q2 2025 and $15.4 million for Q1 2025.